Pharnext announces €20.5 million Bond Loan
![pharnext-logo-400x113](https://ipfpartners.com/wp-content/uploads/2019/05/pharnext-logo-400x113-300x85.png)
Pharnext SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced a financing of up to €20 million through a bond loan with IPF Partners, one of the top providers of alternative financings in the healthcare sector.